TORONTO, ONTARIO--(Marketwire - May 26, 2008) - Patients with Multiple Sclerosis (MS) who take the once-a-week prescription injection AVONEX® (interferon beta-1a) will now be the first in North America to benefit from a free and unique adherence solution program. BioGen Idec Canada, a subsidiary of Biogen Idec Inc., makers of AVONEX, and MEMOTEXT®, provider of personalized adherence solutions, have joined forces to help patients remember to take their medicine.
